Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
BIOMARIN PHARMACEUTICAL INC incurred senior notes of $850 million aggregate principal amount at 5.500% maturing 2026.
- Instrument
- senior notes
- Principal
- $850 million aggregate principal amount
- Rate
- 5.500%
- Maturity
- 2026
- Event
- incurrence
Exact text from the filing
On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BIOMARIN PHARMACEUTICAL INC entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $850 million aggregate principal amount (effective 2026-02-12).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- U.S. Bank Trust Company, National Association, as trustee
- Value
- $850 million aggregate principal amount
- Effective
- 2026-02-12
Exact text from the filing
On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.
View on SEC.gov